Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Drug: Empagliflozin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Abstract Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both m...
Source: Diabetes and Metabolism - May 15, 2017 Category: Endocrinology Authors: Bonnet F, Scheen AJ Tags: Diabetes Metab Source Type: research

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Incidence of adverse cardiovascular events in type  2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata Tags: Original Article Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
ConclusionsAvailable data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
Source: Acta Diabetologica - August 3, 2016 Category: Endocrinology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

The EMPA-REG Study: What has it told us? A Diabetologist’s Perspective
EMPA-REG (1) is the first study to conclusively demonstrate that a medication developed to reduce glycemia (2) in patients with type 2 diabetes mellitus (T2DM) decreases cardiovascular events. In 7020 T2DM patients with established cardiovascular (CV) disease, empagliflozin (pooled 10 and 25 mg/day doses) significantly reduced the primary MACE outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% compared to placebo (HR = 0.86, 95% CI = 0.74-0.99, P=0.04 for superiority). It is noteworthy that a striking disconnect was observed between the three MACE components; (i) for nonfatal MI, the HR (=0.87) decreased s...
Source: Journal of Diabetes and Its Complications - October 21, 2015 Category: Endocrinology Authors: Ralph A. DeFronzo Source Type: research

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Publication date: Available online 18 March 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We a...
Source: The Lancet Diabetes and Endocrinology - March 19, 2016 Category: Endocrinology Source Type: research

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
ConclusionsIn a meta‐analysis of data from 8 randomized trials involving 11292 patients with T2DM at low/medium or high CV risk, empagliflozin was associated with a reduced risk of 4‐point MACE and 3‐point MACE compared with placebo.
Source: Diabetes, Obesity and Metabolism - June 30, 2016 Category: Endocrinology Authors: A. Salsali, G. Kim, H. J. Woerle, U. C. Broedl, S. Hantel Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta ‐analysis of data from randomized placebo‐controlled trials
ConclusionsIn a meta‐analysis of data from 8 randomized trials involving 11292 patients with T2DM at low/medium or high CV risk, empagliflozin was associated with a reduced risk of 4‐point MACE and 3‐point MACE compared with placebo.
Source: Diabetes, Obesity and Metabolism - July 3, 2016 Category: Endocrinology Authors: A. Salsali, G. Kim, H. J. Woerle, U. C. Broedl, S. Hantel Tags: ORIGINAL ARTICLE Source Type: research

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Histo...
Source: Diabetes Care - August 22, 2017 Category: Endocrinology Authors: Marx, N.; McGuire, D. K.; Perkovic, V.; Woerle, H.-J.; Broedl, U. C.; von Eynatten, M.; George, J. T.; Rosenstock, J. Tags: Perspectives in Care Source Type: research